TheranosticTrials.org

Clinical Trial · NCT05580835

PET / MR With PSMA for Diagnosis and Staging of Hepatocellular Carcinoma

Overview

Assess the rate and degree of PSMA uptake in patients with hepatocellular carcinoma submitted to PET/MRI scans. The objective is to evaluate its value on diagnosis and staging of HCC.

Sponsor

University of Saskatchewan

Phase

N/A

Contacts

Carlos Buchpiguel, PhD (STUDY_CHAIR)

Irai S Oliveira, MD (CONTACT)

irai.oliveira@hc.fm.usp.br

5511993662208

Irai S Oliveira, MD (PRINCIPAL_INVESTIGATOR)

Sabrina M Ando, MD (CONTACT)

sabrina.ando@hc.fm.usp.br

5511974777302

ClinicalTrials.gov

NCT05580835

Drug / Compound

PSMA-11

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: HBED-CC

Eligibility

Inclusion

  • * Patients with an imaging diagnosis of HCC by a previous CT or MRI, reviewed by an abdominal radiologist
  • Patients candidates to liver transplant or surgical resection

Exclusion

  • Patients with renal insufficiency;
  • Age under 18
  • * Patients with treated liver lesion without viable tumor
  • Pregnancy
  • Elevated bilirubin levels (\>3 mg/dL)